摘要
目的 :研究高剂量与常规剂量表柔比星 (表阿霉素 ,EPI)在肿瘤化疗患者体内的药物动力学过程 ,并初步探讨剂量 毒副反应相关性。方法 :31例肿瘤患者分两组接受包含 70mg m2 或 12 0mg m2 EPI的联合化疗 ,高效液相色谱法 (HPLC)测定血药浓度 ,3P87程序进行药动学房室模型数据拟合和参数计算。临床评估毒副反应 ,进行高剂量EPI化疗耐受性研究。结果 :一次静脉应用EPI的药物动力学符合三室模型。两种剂量EPI化疗耐受性均良好。结论 :EPI的消除符合三室模型特征 ,具有个体差异大、消除缓慢等特点。高剂量与常规剂量EPI相比较 ,主要药物动力学参数差异无显著性。
Purpose:To study the pharmacokinetics of high dose, conventional dose epirubicin in cancer patients. Methods:Thirty-one cancer patients were given a dose of 120 mg/m 2 epirubicin or a dose of 70 mg/m 2 epirubicin. The concentration of epirubicin in the blood was determined by high-performance liquid chromatographic (HPLC) assay. The modeling data were performed with a compartment pharmacokinetic modeling program (3P87). Clinical toxicity was observed. The relationship between doses and side effects or pharmacolinetics was assessed. Results:The pharmacokinetics of high dose and conventional dose epirubicin were best described by a typical three-compartment model. It showed wide inter-individual variation. Conclusions:The pharmacokinetics of high dose and conventional dose epirubicin were best described by a typical three-compartment model. There was no difference for the pharmacokinetic parameters between high dose and conventional dose.
出处
《中国癌症杂志》
CAS
CSCD
2001年第2期125-127,共3页
China Oncology
